Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. (TRVI) on July 2, 2019, covering events occurring on June 28, 2019. The company is a Delaware corporation with principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Resignation: Mette Kirstine Agger resigned from the Board of Directors, effective June 30, 2019. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Committee Appointment: Michael Heffernan was appointed to the Audit Committee, effective June 30, 2019, to fill the vacancy created by Ms. Agger's resignation.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, risks, contingencies, or unusual items. The document is limited to the disclosure of the director departure and subsequent appointment.
Investor Verification Checklist
- Confirm the effective date of Mette Kirstine Agger's resignation (June 30, 2019).
- Verify the appointment of Michael Heffernan to the Audit Committee.
- Review the company's most recent 10-Q or 10-K for financial metrics not included in this 8-K.